Professor of Clinical Medicine, University of California, San Francisco; Co-Medical Director
UCSF Center for Colitis and Crohn's Disease
San Francisco, CA
Dr. Uma Mahadevan completed a medical degree at the State University of New York, Brooklyn. She completed a residency in internal medicine at Mount Sinai Medical Center, New York, a gastroenterology fellowship at University of California, San Francisco (UCSF), and a fellowship in inflammatory bowel disease (IBD) at Mayo Clinic, Rochester. Dr. Mahadevan currently serves as Professor of Medicine at UCSF and Medical Director of the UCSF Center for Colitis and Crohn's Disease. Certified by the ABIM as a Diplomate in internal medicine and gastroenterology, Dr. Mahadevan is a Fellow of the ACG and the AGA, for whom she is a Chair for the IMIBD Section and on the AGA Council. She is a section editor for the journal Gastroenterology. She is currently Co-Chair of the Research Affairs Committee of the Crohn's and Colitis Foundation and was formerly Chairman of the National Patient Education Committe, as well as Director of Patient Education for WE CARE, an organization of women professionals in IBD. She also served as President of the Northern California Society of Clinical Gastroenterology in 2005. Dr. Mahadevan has published original articles, abstracts, editorials, and invited reviews in such peer-reviewed journals as Gastroenterology, The American Journal of Gastroenterology, Inflammatory Bowel Diseases, and Gut, along with several book chapters. Additionally, Dr. Mahadevan is an editorial board member and reviewer for several journals. Dr. Mahadevan specializes in the treatment of ulcerative colitis, Crohn's disease, and pouchitis. She has a particular interest in pregnancy and fertility in IBD, as well as in clinical trials of experimental therapy for both ulcerative colitis and Crohn's disease. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO), clinical trials in biologic therapy for IBD, and microbiome, environmental and dietary changes among South Asians with IBD.